U.S. Markets close in 4 hrs 30 mins
  • S&P 500

    3,627.12
    +49.53 (+1.38%)
     
  • Dow 30

    30,012.73
    +421.46 (+1.42%)
     
  • Nasdaq

    11,997.04
    +116.40 (+0.98%)
     
  • Russell 2000

    1,848.25
    +29.95 (+1.65%)
     
  • Crude Oil

    45.10
    +2.04 (+4.74%)
     
  • Gold

    1,802.80
    -35.00 (-1.90%)
     
  • Silver

    23.25
    -0.39 (-1.64%)
     
  • EUR/USD

    1.1886
    +0.0041 (+0.3447%)
     
  • 10-Yr Bond

    0.8770
    +0.0200 (+2.33%)
     
  • Vix

    22.07
    -0.59 (-2.60%)
     
  • GBP/USD

    1.3354
    +0.0032 (+0.2417%)
     
  • USD/JPY

    104.6310
    +0.1430 (+0.1369%)
     
  • BTC-USD

    19,225.96
    +774.00 (+4.19%)
     
  • CMC Crypto 200

    382.10
    +12.35 (+3.34%)
     
  • FTSE 100

    6,421.41
    +87.57 (+1.38%)
     
  • Nikkei 225

    26,165.59
    +638.22 (+2.50%)
     

Regeneron Announces Investor Conference Presentations

·2 min read

TARRYTOWN, N.Y., Oct. 27, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:

  • Credit Suisse 29th Annual Virtual Healthcare Conference at 8:45 a.m. EST on Monday, November 9, 2020

  • Cowen Virtual Presentation Series – 2020 IO Next Summit at 1:15 p.m. EST on Friday, November 13, 2020

  • Jefferies Virtual London Healthcare Conference at 7:20 a.m. EST (12:20 p.m. GMT) on Tuesday, November 17, 2020

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays of the webcasts will be archived on the Company's website for at least 30 days.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Contact Information:
Investor Relations
Justin Holko
914.847.7786
justin.holko@regeneron.com

Cision
Cision

View original content:http://www.prnewswire.com/news-releases/regeneron-announces-investor-conference-presentations-301161036.html

SOURCE Regeneron Pharmaceuticals, Inc.